Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Eligibility criteria
Qualifiers
Patients with histological confirmation of a solid tumor.
Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
Patient must be ≥ 18 years old.
All patients must have signed and dated an informed consent form.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 1 trial groupSponsors and collaborators
University Health Network, Toronto
Lead sponsor
Princess Margaret Hospital, Canada
Collaborator
Source ClinicalTrials.gov